Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Idiopathic Pulmonary Fibrosis Pipeline Highlights - 2017-2020 Update - ResearchAndMarkets.com

Research and Markets
Posted on: 23 Feb 18

The "Idiopathic Pulmonary Fibrosis Pipeline Highlights - 2017 Update" drug pipelines has been added to ResearchAndMarkets.com's offering.

The latest report from, Idiopathic Pulmonary Fibrosis Pipeline Highlights - 2017 Update, provides most up-to-date information on key pipeline products in the global Idiopathic Pulmonary Fibrosis market. It covers emerging therapies for Idiopathic Pulmonary Fibrosis in active clinical development stages including early and late stage clinical trials.

The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Idiopathic Pulmonary Fibrosis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Idiopathic Pulmonary Fibrosis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Idiopathic Pulmonary Fibrosis pipeline products by the company.

Short-term Launch Highlights:

Find out which Idiopathic Pulmonary Fibrosis pipeline products will be launched in the US and Ex-US till 2020.

Key Topics Covered:

1. Idiopathic Pulmonary Fibrosis Pipeline by Stages

2. Idiopathic Pulmonary Fibrosis Pipeline by Drug Class

3. Idiopathic Pulmonary Fibrosis Pipeline by Company

4. Idiopathic Pulmonary Fibrosis Phase 3 Clinical Trial Insights

5. Idiopathic Pulmonary Fibrosis Phase 2 Clinical Trial Insights

6. Idiopathic Pulmonary Fibrosis Phase 1 Clinical Trial Insights

7. Idiopathic Pulmonary Fibrosis Preclinical Research Insights

8. Idiopathic Pulmonary Fibrosis Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xlgsln/idiopathic?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180223005520/en/

Business Wire
www.businesswire.com

Last updated on: 23/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.